


Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

1. (Currently amended) A compound of formula (I) :



wherein:

n is 0, 1, or 2;

t is 0 or 1;

X is -NH- , -O- , $\text{-R}^{10}\text{-}$, $\text{-R}^{10}\text{O-}$, $\text{-R}^{10}\text{OR}^{10}\text{-}$, $\text{-NR}^{10}\text{-}$, $\text{-R}^{10}\text{N-}$, $\text{-R}^{10}\text{NR}^{10}\text{-}$, $\text{-R}^{10}\text{S(O)}_m\text{-}$, or $\text{-R}^{10}\text{S(O)}_m\text{R}^{10}\text{-}$;

Y is -C(O)- or $\text{-S(O)}_m\text{-}$;

each R is the same or different and is independently selected from the group consisting of

halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $\text{-R}^{10}\text{cycloalkyl}$,
Ay, $\text{-NHR}^{10}\text{Ay}$, Het, -NHHet , $\text{-NHR}^{10}\text{Het}$, -OR^2 , -OAY , -OHet , $\text{-R}^{10}\text{OR}^2$, $\text{-NR}^2\text{R}^3$,
 $\text{-NR}^2\text{Ay}$, $\text{-R}^{10}\text{NR}^2\text{R}^3$, $\text{-R}^{10}\text{NR}^2\text{Ay}$, $\text{-R}^{10}\text{C(O)R}^2$, -C(O)R^2 , $\text{-CO}_2\text{R}^2$, $\text{-R}^{10}\text{CO}_2\text{R}^2$,
 $\text{-C(O)NR}^2\text{R}^3$, -C(O)Ay , $\text{-C(O)NR}^2\text{Ay}$, -C(O)Het , $\text{-C(O)NHR}^{10}\text{Het}$, $\text{-R}^{10}\text{C(O)NR}^2\text{R}^3$,
 $\text{-C(S)NR}^2\text{R}^3$, $\text{-R}^{10}\text{C(S)NR}^2\text{R}^3$, $\text{-R}^{10}\text{NHC(NH)NR}^2\text{R}^3$, $\text{-C(NH)NR}^2\text{R}^3$,
 $\text{-R}^{10}\text{C(NH)NR}^2\text{R}^3$, $\text{-S(O)}_2\text{NR}^2\text{R}^3$, $\text{-S(O)}_2\text{NR}^2\text{Ay}$, $\text{-R}^{10}\text{SO}_2\text{NHCOR}^2$, $\text{-R}^{10}\text{SO}_2\text{NR}^2\text{R}^3$,
 $\text{-R}^{10}\text{SO}_2\text{R}^2$, $\text{-S(O)}_m\text{R}^2$, $\text{-S(O)}_m\text{Ay}$, cyano, nitro, or azido;

each R^1 is the same or different and is independently selected from the group
consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
 $\text{-R}^{10}\text{cycloalkyl}$, Ay, $\text{-NHR}^{10}\text{Ay}$, Het, -NHHet , $\text{-NHR}^{10}\text{Het}$, -OR^2 , -OAY , -OHet ,

$-R^{10}OR^2$, $-NR^2R^3$, $-NR^2Ay$, $-R^{10}NR^2R^3$, $-R^{10}NR^2Ay$, $-R^{10}C(O)R^2$, $-C(O)R^2$, $-CO_2R^2$,
 $-R^{10}CO_2R^2$, $-C(O)NR^2R^3$, $-C(O)Ay$, $-C(O)NR^2Ay$, $-C(O)Het$, $-C(O)NHR^{10}Het$,
 $-R^{10}C(O)NR^2R^3$, $-C(S)NR^2R^3$, $-R^{10}C(S)NR^2R^3$, $-R^{10}NHC(NH)NR^2R^3$,
 $-C(NH)NR^2R^3$, $-R^{10}C(NH)NR^2R^3$, $-S(O)_2NR^2R^3$, $-S(O)_2NR^2Ay$, $-R^{10}SO_2NHCOR^2$,
 $-R^{10}SO_2NR^2R^3$, $-R^{10}SO_2R^2$, $-S(O)_mR^2$, $-S(O)_mAy$, cyano, nitro, or azido;

each m independently is 0, 1, or 2;

each R^{10} is the same or different and is independently selected from alkylene, cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5;

each of R^2 and R^3 are the same or different and are independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, $-R^{10}$ cycloalkyl, $-R^{10}OH$, $-R^{10}(OR^{10})_w$, and $-R^{10}NR^4R^5$;

w is 1-10;

each of R^4 and R^5 are the same or different and are independently selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

Ay represents an aryl group;

Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;


ring A is aryl or heteroaryl;

provided that when the A ring is aryl, t is 0, and Y is SO_2 , then p is not 0; or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) The compound of claim 1 wherein alkyl is C_1 - C_6 alkyl, alkoxy is C_1 - C_6 alkoxy, haloalkyl is C_1 - C_6 haloalkyl, alkylene is C_1 - C_6 alkylene, and alkenylene is C_1 - C_6 alkenylene.
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Currently amended) The compound of claim 1 wherein t is 1, ~~Y is $-S(O)_m$,~~
and X is $-NH-$, $-O-$, or $-R^{10}$.
7. (Cancelled)

8. (Original) The compound of claim 1 wherein p is 1 or more and R is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, cyano, nitro, or azido.
9. (Original) The compound of claim 8 wherein R is halogen, alkyl, haloalkyl.
10. (Original) The compound of claim 9 wherein R is substituted *para* to the depicted N atom.
11. (Original) The compound of claim 10 wherein R is halogen.
12. (Original) The compound of claim 11 wherein R is Br or Cl.
13. (Original) The compound of claim 1 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
14. (Original) The compound of claim 13 wherein R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.
15. (Original) The compound of claim 14 wherein R^2 and R^3 each are C_1 - C_6 alkyl.
16. (Original) The compound of claim 14 wherein R^1 is selected from halogen, alkyl, or $-OR^2$.
17. (Original) The compound of claim 16 wherein said halogen is fluoro or chloro, said alkyl is methyl, and said $-OR^2$ is alkoxy.
18. (Cancelled)
19. (Cancelled)
20. (Original) The compound of claim 19 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
21. (Original) The compound of claim 20 wherein q is 1 or more and R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.
22. (Original) The compound of claim 1 wherein the A ring is heteroaryl.
23. (Original) The compound of claim 22 wherein the heteroaryl is pyridyl.
24. (Original) The compound of claim 23 wherein q is 0 or 1.

25. (Previously presented) The compound of claim 24 wherein when q is 1, then R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, Ay, Het, cyano, nitro, or azido.
26. (Original) The compound of claim 25 wherein when q is 1, then R^1 is selected from halogen, alkyl, haloalkyl, $-OR^2$, $-NR^2R^3$, $-C(O)R^2$, $-CO_2R^2$, or cyano.
27. (Original) The compound of claim 1 wherein p is 1, R is halogen, n is 1, Y is $-C(O)-$, t is 0, ring A is heteroaryl, and q is 0.
28. (Original) The compound of claim 27 wherein R is chloro and ring A is pyridyl.
29. (Original) A compound selected from:



30. (Currently amended) The compound of claim 1 selected from the group consisting of:

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(4-methoxyphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(4-methoxy-2-methylphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-(3-chloro-4-methoxyphenyl)urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-[4-(dimethylamino)phenyl]urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-[(1*S*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-phenylacetamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylpropanamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-dichlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;
N-(2,3,4,9-Tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;
N-Phenyl-*N'*-(2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)urea;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-imidazole-5-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-5-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-3-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

31. (Currently amended) The compound of claim 1 selected from the group consisting of:

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-[4-(dimethylamino)phenyl]urea;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;
N-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;

N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

32. (Currently amended) The compound of claim 1 selected from the group consisting of:

N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-(6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;
N-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;
N-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;
N-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide; and
N-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide.

- 33. (Cancelled)
- 34. (Cancelled)
- 35. (Currently amended) A pharmaceutical composition comprising a compound according to any of claims 1 to 33 30 to 32, and a pharmaceutically acceptable carrier.
- 36 – 44 Cancelled.
- 45. (Currently amended) A method for the treatment of a papovavirus infection selected from the group consisting of polyoma virus infection and papilloma virus infection comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any of claim 1 claims 30 to 32.
- 46. (Currently amended) A method for the treatment of conditions or disorders due to HPV infection selected from the group consisting of genital warts and cervical dysplasia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any of claim 1 claims 30 to 32.
- 47. (Cancelled)